We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Janssen-Cilag Ltd

50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG, UK
Telephone: +44 1494 567 567
Fax: +44 1494 567 568
Medical Information Direct Line: +353 1 800 709 122
Medical Information e-mail: medinfo@janssen-cilag.co.uk
Customer Care direct line: +353 1 620 2300
Medical Information Facsimile: +44 (0) 1494 567 445
Patient Information Leaflet last updated on medicines.ie: 2/14/2018
PIL Imbruvica 140 mg hard capsules

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 2/14/2018 and displayed until Current
Reasons for adding or updating:
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
Updated on 11/8/2017 and displayed until 2/14/2018
Reasons for adding or updating:
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision
Updated on 8/25/2017 and displayed until 11/8/2017
Reasons for adding or updating:
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision
Updated on 2/22/2017 and displayed until 8/25/2017
Reasons for adding or updating:
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision
Updated on 1/16/2017 and displayed until 2/22/2017
Reasons for adding or updating:
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
Updated on 9/1/2016 and displayed until 1/16/2017
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 8/17/2016 and displayed until 9/1/2016
Reasons for adding or updating:
  • Change to drug interactions
  • Change to date of revision
Updated on 5/31/2016 and displayed until 8/17/2016
Reasons for adding or updating:
  • Change to, or new use for medicine
  • Change to side-effects
  • Change to date of revision
Updated on 3/24/2016 and displayed until 5/31/2016
Reasons for adding or updating:
  • Change to side-effects
Updated on 11/18/2015 and displayed until 3/24/2016
Reasons for adding or updating:
  • Change to drug interactions
Updated on 8/19/2015 and displayed until 11/18/2015
Reasons for adding or updating:
  • Change to side-effects
Updated on 7/13/2015 and displayed until 8/19/2015
Reasons for adding or updating:
  • Change to, or new use for medicine
  • Change to side-effects
  • Change to dosage and administration
Updated on 3/25/2015 and displayed until 7/13/2015
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 10/21/2014 and displayed until 3/25/2015
Reasons for adding or updating:
  • New PIL for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Ibrutinib